Proteína beta traza como biomarcador en el diagnóstico clínico temprano de nefropatía diabética en pacientes mayores de 40 años con diabetes mellitus II

Abstract

Diabetic Nephropathy (DN) is an important public health problem because it is one of the main causes of chronic and terminal renal disease. Beta-trace protein (BTP) could be a potential biomarker in the early clinical diagnosis of this disease. Objective: To describe beta trace protein as a biomarker in the early clinical diagnosis of diabetic nephropathy in patients older than 40 years with diabetes mellitus type II. Methodology: Descriptive revision of descriptive characteristics, based on the search for information in various scientific databases, for its analysis, with the purpose of demonstrating the relationship between the current studies and the usefulness of PBT, systematized in tables and infographics. Results: The studies in general indicated that PBT is an important biomarker in the early detection of ND, observing high levels in serum and urine. In addition, it has a moderate discriminatory capacity between patients with and without DN (area under the curve AUC: 0.731), an overall accuracy of 70% classified as a reliable test. Compared to creatinine, BTP offers advantages in the estimation of Glomerular Filtration rate (GFR), being a more specific marker. Conclusions: BPT is considered a promising biomarker for early detection of DN and monitoring of renal function in patients with DM2. PBT demonstrated a moderate ability to discriminate between patients who suffer from or not DN, and finally, it was evidenced that this marker has a significant negative correlation with GFR in specific populations, being better that the one with creatinine.